Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 8 | 2025 | 177 | 3.760 |
Why?
|
| Breast Neoplasms | 15 | 2024 | 3054 | 2.860 |
Why?
|
| Receptor, ErbB-2 | 7 | 2024 | 259 | 2.410 |
Why?
|
| Neoadjuvant Therapy | 11 | 2024 | 400 | 2.370 |
Why?
|
| Mastectomy, Segmental | 2 | 2024 | 101 | 1.680 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1573 | 1.400 |
Why?
|
| Receptors, Progesterone | 2 | 2024 | 179 | 1.040 |
Why?
|
| Receptors, Estrogen | 2 | 2024 | 401 | 0.970 |
Why?
|
| Immunoconjugates | 2 | 2024 | 119 | 0.940 |
Why?
|
| Neoplasm Staging | 9 | 2025 | 2032 | 0.900 |
Why?
|
| Immunotherapy | 3 | 2025 | 725 | 0.860 |
Why?
|
| Artificial Intelligence | 2 | 2025 | 356 | 0.850 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 443 | 0.800 |
Why?
|
| Genomics | 2 | 2024 | 806 | 0.750 |
Why?
|
| Precision Medicine | 2 | 2024 | 425 | 0.690 |
Why?
|
| Specimen Handling | 1 | 2021 | 103 | 0.680 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 17 | 0.680 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 37 | 0.680 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 1271 | 0.680 |
Why?
|
| Medical Oncology | 1 | 2024 | 393 | 0.660 |
Why?
|
| Prognosis | 7 | 2024 | 3871 | 0.650 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 304 | 0.620 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2020 | 98 | 0.620 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 22 | 0.610 |
Why?
|
| Pneumococcal Infections | 1 | 2019 | 50 | 0.600 |
Why?
|
| Humans | 32 | 2025 | 92348 | 0.580 |
Why?
|
| Neoplasms | 3 | 2024 | 3122 | 0.580 |
Why?
|
| Female | 23 | 2025 | 47902 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 1398 | 0.540 |
Why?
|
| Patient Selection | 1 | 2020 | 689 | 0.520 |
Why?
|
| Internal Medicine | 1 | 2020 | 366 | 0.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 2555 | 0.430 |
Why?
|
| Middle Aged | 13 | 2025 | 27050 | 0.370 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 1136 | 0.350 |
Why?
|
| Antineoplastic Agents | 1 | 2022 | 2366 | 0.350 |
Why?
|
| Internship and Residency | 1 | 2020 | 1087 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2025 | 9693 | 0.330 |
Why?
|
| Papillomavirus Infections | 2 | 2025 | 274 | 0.330 |
Why?
|
| Machine Learning | 2 | 2024 | 299 | 0.320 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 285 | 0.320 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 127 | 0.320 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 521 | 0.280 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 2394 | 0.270 |
Why?
|
| Aged | 8 | 2025 | 19947 | 0.260 |
Why?
|
| United States | 4 | 2025 | 7369 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 485 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2023 | 2980 | 0.200 |
Why?
|
| Adult | 8 | 2025 | 27551 | 0.200 |
Why?
|
| Anthracyclines | 1 | 2022 | 35 | 0.190 |
Why?
|
| Hormones | 1 | 2022 | 141 | 0.190 |
Why?
|
| Contrast Media | 2 | 2023 | 1076 | 0.180 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.180 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
|
| Connecticut | 1 | 2020 | 26 | 0.170 |
Why?
|
| Shift Work Schedule | 1 | 2020 | 6 | 0.170 |
Why?
|
| Work Schedule Tolerance | 1 | 2020 | 37 | 0.170 |
Why?
|
| Software | 2 | 2024 | 677 | 0.160 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 88 | 0.160 |
Why?
|
| Male | 6 | 2025 | 43928 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1733 | 0.160 |
Why?
|
| Automation | 1 | 2020 | 112 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1178 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2020 | 80 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 531 | 0.160 |
Why?
|
| Algorithms | 2 | 2024 | 1961 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2020 | 314 | 0.150 |
Why?
|
| Maxillary Sinus | 1 | 2019 | 22 | 0.150 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 1804 | 0.150 |
Why?
|
| Streptococcus pneumoniae | 1 | 2019 | 51 | 0.150 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 390 | 0.150 |
Why?
|
| Carcinoma | 1 | 2022 | 438 | 0.150 |
Why?
|
| Mouth Neoplasms | 1 | 2020 | 198 | 0.150 |
Why?
|
| Age Factors | 1 | 2023 | 1903 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1398 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 871 | 0.140 |
Why?
|
| Bacteremia | 1 | 2019 | 105 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 1075 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3775 | 0.140 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 1150 | 0.130 |
Why?
|
| Logistic Models | 1 | 2020 | 1239 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2020 | 552 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1480 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3516 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2025 | 8729 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2368 | 0.110 |
Why?
|
| Mutation | 2 | 2023 | 4213 | 0.100 |
Why?
|
| Papillomaviridae | 2 | 2025 | 165 | 0.100 |
Why?
|
| Doxorubicin | 2 | 2024 | 296 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2733 | 0.090 |
Why?
|
| Breast | 2 | 2023 | 289 | 0.080 |
Why?
|
| Risk Factors | 1 | 2021 | 5705 | 0.080 |
Why?
|
| Kinetics | 2 | 2023 | 1552 | 0.080 |
Why?
|
| Mifepristone | 1 | 2025 | 45 | 0.060 |
Why?
|
| Albumins | 1 | 2025 | 134 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2024 | 78 | 0.050 |
Why?
|
| Computers | 1 | 2024 | 111 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2024 | 304 | 0.050 |
Why?
|
| Camptothecin | 1 | 2024 | 198 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 141 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2025 | 495 | 0.050 |
Why?
|
| Hydrodynamics | 1 | 2022 | 19 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 786 | 0.050 |
Why?
|
| Clinical Decision-Making | 1 | 2024 | 290 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 188 | 0.050 |
Why?
|
| Computational Biology | 1 | 2024 | 568 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2023 | 200 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 2008 | 0.040 |
Why?
|
| Survival Rate | 1 | 2023 | 1926 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 4474 | 0.030 |
Why?
|